Northwell intracoronary brachytherapy for the treatment of recurrent drug eluting stent in‐stent restenosis (NITDI study group)

Meraj, Perwaiz; Patel, Krunalkumar; Patel, Amitkumar; Doshi, Rajkumar; Srinivas, G.; Jauhar, Rajiv; Kaplan, Barry M.; Garzon, Ruby; Sharma, Anurag; Cao, Yejie; Molina, F. Diaz; Sharma, Rajiv

doi:10.1002/ccd.28708

Cited by 7 publications

(10 citation statements)

References 20 publications

(44 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Multiple studies have demonstrated lower rates of MACE with VBT compared to re-DES for DES-ISR (Table 4, Ref. [18,22,35,80,[82][83][84][85][86], Supplementary Table 1), Fig. 3.…”

Section: Efficacy 431 Major Adverse Cardiac Events (Mace)mentioning

confidence: 98%

“…The patients in this study either had VBT for DES-ISR initially or presented with symptoms including angina requiring VBT (Table 1, Ref. [18,22,35,80,[82][83][84][85]). The patients presenting with ST segment elevation myocardial infarction (STEMI), cardiogenic shock or angiographic stent thrombosis were excluded from some of the studies (Table 1).…”

Section: Patient Demographic and Baseline Clinical Characteristicsmentioning

confidence: 99%

“…The baseline clinical characteristics of the patients in the individual studies are summarized in Table 2 (Ref. [18,22,35,80,[82][83][84][85] Majority of the patients had cardiac risk factors including age >65, male gender, hypertension, hyperlipidaemia and high body mass index (BMI) (Table 2). A significant proportion of patients had risk factors including diabetes, prior CABG and current smoking.…”

Section: Patient Demographic and Baseline Clinical Characteristicsmentioning

confidence: 99%

“…The strontium/Yttrium 90 beta source was used across all studies with some utilization of the phosphorus-32 beta source and iridium-192 beta source (Table 3, Ref. [18,22,35,80,[82][83][84][85]).…”

Section: Lesion Characteristics and Type Of Radiationmentioning

confidence: 99%

See 3 more Smart Citations

An in-depth review of retrospective studies to assess the role of vascular brachytherapy for the treatment of complex patients with multiple risk factors for DES-ISR

Mittal¹,

Dhaliwal²,

Bhullar³

et al. 2022

Rev. Cardiovasc. Med.

View full text Add to dashboard Cite

Background: Vascular brachytherapy (VBT) used to be an effective treatment modality for management of in-stent stenosis but was superceded by drug eluting stents (DES) which had shown a greater efficacy. However, there is no clear evidence to support superior management for in-stent restenosis (ISR) which continues to be a challenge. Methods: We conducted a systematic review of the literature and appraised PubMed, Medline, Web of science, ProQuest and Cochrane databases from 2000 to 2020. We assessed comparative outcomes including efficacy (as assessed by measuring major adverse cardiac events, target vessel revascularisation, target lesion revascularisation, all-cause mortality, target lesion myocardial infarction and stent thrombosis) and safety of VBT. Results: Of 1083 records obtained, a total of 8 retrospective studies met the inclusion criteria. In the included studies, major adverse cardiac events (MACE) rates ranged from 10% to 17.5% in the VBT group compared to 14.1% to 28.2% in the re-DES group at one year follow up. There were lower rates of target vessel revascularisation (VBT 10-22.8%; control 18-22.9%) and target lesion revascularisation (VBT 10-14.1%, Control 8-22.1%) between the VBT and re-DES groups. There were significantly low rates of all-cause mortality (1-5.4%), target lesion myocardial infarction (0-7%) and stent thrombosis (0-2.1%) in the VBT group at one year. Conclusions: VBT is considered to be an effective and safe treatment strategy in complex patients with multiple risk factors for DES-ISR in initial reports. There are no long-term comparison studies available beyond 1 year. There is a need for randomised controlled trials to objectively assess the role of VBT compared to DES and drug coated balloons.

show abstract

“…Multiple studies have demonstrated lower rates of MACE with VBT compared to re-DES for DES-ISR (Table 4, Ref. [18,22,35,80,[82][83][84][85][86], Supplementary Table 1), Fig. 3.…”

Section: Efficacy 431 Major Adverse Cardiac Events (Mace)mentioning

confidence: 98%

Section: Patient Demographic and Baseline Clinical Characteristicsmentioning

confidence: 99%

Section: Patient Demographic and Baseline Clinical Characteristicsmentioning

confidence: 99%

Section: Lesion Characteristics and Type Of Radiationmentioning

confidence: 99%

See 2 more Smart Citations

An in-depth review of retrospective studies to assess the role of vascular brachytherapy for the treatment of complex patients with multiple risk factors for DES-ISR

Mittal¹,

Dhaliwal²,

Bhullar³

et al. 2022

Rev. Cardiovasc. Med.

View full text Add to dashboard Cite

show abstract

“…While stenting within a restenosis is ubiquitous, stenting when there are already two layers of stents is generally disapproved of. Beta radiation, with the Novoste Beta‐cath system, once again appears to be an excellent option in these complicated and previously treated lesions 4 . While drug eluting balloons show promising results in the treatment of in‐stent restenosis they are currently not widely available in the United States.…”

mentioning

confidence: 99%